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Abstract
Background: Impaired γ-aminobutyric acid (GABA) signaling may contribute to the emergence of cognitive deficits and 
subcortical dopaminergic hyperactivity in patients with schizophrenia and related psychotic disorders. Against this 
background, it has been proposed that pharmacological interventions targeting GABAergic dysfunctions may prove useful in 
correcting such cognitive impairments and dopaminergic imbalances.
Methods: Here, we explored possible beneficial effects of the benzodiazepine-positive allosteric modulator SH-053-2’F-S-CH3, 
with partial selectivity at the α2, α3, and α5 subunits of the GABAA receptor in an immune-mediated neurodevelopmental 
disruption model. The model is based on prenatal administration of the viral mimetic polyriboinosinic-polyribocytidilic acid 
[poly(I:C)] in mice, which is known to capture various GABAergic, dopamine-related, and cognitive abnormalities implicated 
in schizophrenia and related disorders.
Results: Real-time polymerase chain reaction analyses confirmed the expected alterations in GABAA receptor α subunit 
gene expression in the medial prefrontal cortices and ventral hippocampi of adult poly(I:C) offspring relative to control 
offspring. Systemic administration of SH-053-2’F-S-CH3 failed to normalize the poly(I:C)-induced deficits in working memory 
and social interaction, but instead impaired performance in these cognitive and behavioral domains both in control and 
poly(I:C) offspring. In contrast, SH-053-2’F-S-CH3 was highly effective in mitigating the poly(I:C)-induced amphetamine 
hypersensitivity phenotype without causing side effects in control offspring.
Conclusions: Our preclinical data suggest that benzodiazepine-like positive allosteric modulators with activity at the α2, α3, 
and α5 subunits of the GABAA receptor may be particularly useful in correcting pathological overactivity of the dopaminergic 
system, but they may be ineffective in targeting multiple pathological domains that involve the co-existence of psychotic, 
social, and cognitive dysfunctions.
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Introduction
The central γ-aminobutyric acid (GABA) system is strongly 
implicated in cognitive processes. Accumulating evidence sug-
gests that GABAergic interneurons critically regulate neuronal 
oscillatory activity (Gonzalez-Burgos and Lewis, 2012), which 
in turn is believed to serve various complex functions, includ-
ing perception, cognition, and memory (Gonzalez-Burgos et al., 
2011; Lewis et al., 2012). On these bases, various cognitive deficits 
found in psychiatric disorders with neurodevelopmental com-
ponents may, at least in part, stem from a dysregulated inhibi-
tory GABAergic interneuron network (Gonzalez-Burgos et  al., 
2011; Lewis et al., 2012; Volk and Lewis, 2013). Altered pre- and 
post-synaptic markers of cortical and hippocampal GABAergic 
neurotransmission are, in fact, among the most consistently 
observed abnormalities in developmental psychiatric disorders, 
most notably schizophrenia (Benes and Berretta, 2001; Volk and 
Lewis, 2013). Post-mortem studies conducted in schizophrenic 
patients report reduced expression levels of specific GABAergic 
interneuron markers, including parvalbumin and somatostatin 
(Hashimoto, Arion, et al., 2008; Morris et al., 2008; Fung et al., 2010; 
Konradi et al., 2011), along with deficient expression of various 
presynaptic regulators of GABA neurotransmission such as the 
67 kDA isoform of the GABA synthesizing enzyme glutamic acid 
decarboxylase (GAD67) and the GABA transporter 1 (Hashimoto, 
Bazmi, et al., 2008). These changes are further accompanied by 
altered levels of GABAA receptor subunits, including increased 
α2 subunits and decreased α1, α4, and α5 subunits in cortical 
layers of patients with schizophrenia (Hashimoto, Arion, et al., 
2008; Hashimoto, Bazmi, et al., 2008; Duncan et al., 2010; Beneyto 
et al., 2011).
In addition to their involvement in cognitive processes, 
GABA-mediated inhibitory networks are also believed to criti-
cally regulate subcortical dopaminergic functions. According to 
a recent hypothesis (Lodge and Grace, 2011; Grace, 2012), disin-
hibition of the (ventral) hippocampus resulting from intrahip-
pocampal impairments in GABAergic signaling could lead to 
a pathological hyperactivity of the (ventral) hippocampus and 
subsequent increase in mesoaccumbal dopamine system func-
tion. Such hippocampal abnormalities and states of subcortical 
hyperdopaminergia are prominent features of schizophrenia 
and related psychotic disorders (Zierhut et al., 2010; Lodge and 
Grace, 2011).
Against these backgrounds, it has been proposed that 
pharmacological interventions targeting GABA abnormali-
ties may prove useful in correcting both cognitive impair-
ments and dopaminergic dysfunctions present in patients 
with schizophrenia (Guidotti et  al., 2005; Stan and Lewis, 
2012). A first line of evidence supporting this hypothesis was 
derived from a small placebo-controlled clinical trial suggest-
ing that treatment with a benzodiazepine-like agent with 
preferential activity at the α2/α3 subunit of GABAA receptors 
can improve cognitive and electrophysiological measures of 
prefrontal functions in individuals with chronic schizophrenia 
(Lewis et al., 2008). Such pro-cognitive effects associated with 
positive allosteric modulation of the α2/α3 subunit, however, 
could not be replicated in a larger randomized clinical trial 
(Buchanan et al., 2011). In contrast, a novel α5 GABAA recep-
tor-positive allosteric modulator has been shown to reverse 
hyperactivation of the dopamine system in the methylazox-
ymethanol acetate (MAM)-based neurodevelopmental disrup-
tion model of schizophrenia (Gill et al., 2011), indicating that 
such GABAergic modulation may be useful in targeting posi-
tive symptoms of schizophrenic disease.
In the present study, we used an established immune-
mediated neurodevelopmental disruption model to test the 
behavioral effects of SH-053-2’F-S-CH3, a relatively novel benzo-
diazepine positive allosteric modulator (PAM) with partial selec-
tivity at the α2, α3, and α5 subunits (Fischer et al., 2010; Savić 
et al., 2010). The chosen model is based on prenatal administra-
tion of the viral mimetic polyriboinosinic-polyribocytidilic acid 
[poly(I:C)] in mice, which is known to capture a wide spectrum of 
behavioral and cognitive abnormalities relevant to neurodevel-
opmental psychiatric disorders (reviewed in Meyer and Feldon, 
2010; Meyer, 2014). The prenatal poly(I:C) model has been estab-
lished in relation to epidemiological studies showing increased 
risk of schizophrenia and related disorders following prenatal 
maternal exposure to infection or inflammation (Brown and 
Derkits, 2010). Importantly, prenatal poly(I:C) treatment in mice 
is capable of inducing a wide range of schizophrenia-relevant 
prefrontal and hippocampal GABAergic abnormalities in adult 
offspring, including reduced mRNA and/or protein expression of 
GAD65, GAD67, and parvalbumin (Meyer et al., 2008; Piontkewitz 
et al., 2012; Richetto et al, 2013, 2014). Mice exposed prenatally 
to poly(I:C) also show diminished prefrontal expression of the 
α4 and α5 subunits of GABAA receptors (Richetto et al., 2014) and 
increased α2-GABAA receptor immunoreactivity at axon initial 
segments (Nyffeler et al., 2006; Meyer et al., 2008), akin to post-
mortem findings in schizophrenia (Volk et al., 2002; Hashimoto, 
Arion, et al., 2008; Beneyto et al., 2011). These GABAergic changes 
are further paralleled by schizophrenia-relevant behavioral and 
cognitive dysfunctions, including impaired working memory 
and cognitive flexibility, reduced social approach behavior, and 
increased amphetamine (AMPH) sensitivity (Zuckerman et  al., 
2003; Meyer et al., 2005, 2008; Bitanihirwe, Peleg-Raibstein, et al., 
2010; Bitanihirwe, Weber, et al. 2010; Connor et al., 2012; Richetto 
et al., 2013, 2014). Based on these findings, we tested whether 
positive allosteric modulation of the α2, α3, and α5 GABAA recep-
tor subunits by systemic SH-053-2’F-S-CH3 treatment may miti-
gate working memory deficiency, social interaction deficits, and 
AMPH hypersensitivity in adult offspring prenatally exposed to 
poly(I:C).
Methods
Animals
C57BL6/N mice were used throughout the study. This mouse 
strain was chosen based on our previous work investigating 
the long-term consequences of prenatal poly(I:C) treatment in 
mice (e.g., Giovanoli et al., 2014). Female and male breeders were 
obtained from our in-house, specific pathogen–free colony at the 
age of 12–14 weeks. Breeding began after 2 weeks of acclimatiza-
tion to the new animal holding room, which was a temperature- 
and humidity-controlled (21 ± 11°C and 55 ± 5%, respectively) 
holding facility under a reversed 12 h light and 12 h dark cycle 
(lights off at 08:00 h). All animals had ad libitum access to stand-
ard rodent chow (Kliba 3430, Provimi Kliba) and water through-
out the study. All procedures described in the present study had 
been previously approved by the Cantonal Veterinarian’s Office 
of Zurich.
Maternal Immune Activation During Pregnancy
Female mice were subjected to a timed mating procedure as 
described previously (Meyer et  al., 2005). Pregnant dams on 
gestation day 17 (GD 17)  received either a single injection of 
poly(I:C) (potassium salt; Sigma-Aldrich) at a dose of 5 mg/kg or 
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vehicle (VEH; sterile pyrogen-free 0.9% NaCl) according to pro-
tocols established before (Meyer et al., 2008; Bitanihirwe, Peleg-
Raibstein, et al., 2010: Bitanihirwe, Weber, et al., 2010; Richetto 
et  al., 2013, 2014; see also Supplementary Figure  1). The late 
gestational stage (i.e., GD 17) was selected because of our previ-
ous findings showing that GD17 poly(I:C) treatment is capable 
of inducing working memory deficiency and various pre- and 
postsynaptic GABAergic abnormalities in adulthood (Meyer 
et  al., 2008; Richetto et  al., 2013, 2014). Poly(I:C) was dissolved 
in sterile pyrogen-free 0.9% NaCl (VEH) solution to yield a final 
concentration of 1.0 mg/ml and was administered via the intra-
venous (i.v) route at the tail vein under mild physical constraint 
as fully described elsewhere (Meyer et  al., 2005). All solutions 
were freshly prepared on the day of administration and injected 
with a volume of 5 ml/kg.
Allocation and Testing of Offspring
All offspring were weaned and sexed at postnatal day 21 
(Supplementary Figure  1). Littermates of the same sex were 
caged separately and maintained in groups of 2–4 animals per 
cage as described above. Only male mice were included in all 
experiments, to circumvent bias arising from sexual dimor-
phism. A first cohort of behaviorally naïve male animals com-
prising of 11 control (CON) and 9 poly(I:C) (POL) offspring was 
allocated to gene expression analyses of GABAA receptor subu-
nits in prefrontal and hippocampal tissues (see below). A sec-
ond cohort of male animals comprising of 34 CON and 34 POL 
offspring was assigned to the behavioral and cognitive testing 
(Supplementary Figure  1), which included (1) spatial working 
memory in the Y-maze, (2) social approach and cognition, and 
(3) AMPH sensitivity tests (see below). To minimize the number 
of animals required to complete all tests of interest, mice were 
repeatedly tested, starting with the spatial working memory 
test and ending with the AMPH sensitivity test. A resting period 
of at least 1 week was inserted between each of these tests so 
as to allow sufficient drug wash-out from one test to another 
(Supplementary Figure 1). Previous drug histories (i.e., SH-053-
2’F-S-CH3 or VEH treatment, see below) were counterbalanced 
across the prenatal treatment conditions from one test to 
another in order to further minimize possible confounds from 
drug carry-over effects. CON and POL offspring in both cohorts 
used in this study stemmed from multiple independent litters 
(19 CON litters and 18 POL litters) in order to avoid litter effects 
(Zorrilla 1997). Hence, 1–2 offspring per litter were used either 
for the gene expression analyses or the behavioral and cogni-
tive testing.
The behavioral testing was always conducted during the ani-
mals’ active phase (i.e., during the dark phase of the reversed 
light-dark cycle between 09:00 and 18:00 h). The time of daily 
testing was counterbalanced across the different experimen-
tal groups. To facilitate the visualization of spatial cues and to 
enable adequate video recordings, behavioral testing required 
that the animals were briefly exposed to a dimly-lit room. All 
experiments were conducted once the offspring reached the 
adult stage of development (i.e., from 14 weeks of age onwards).
Gene Expression Analysis by Quantitative  
Real-Time PCR
Fresh brain tissue was collected and prepared for gene expres-
sion analysis by quantitative real-time polymerase chain reac-
tion (PCR) as fully described in the Supplementary Materials. 
Following total RNA extraction, the samples were processed for 
real-time PCR to assess the five different α subunits (α1–α5) of 
GABAA receptors using protocols established previously (Guidotti 
et  al., 2012; Richetto et  al., 2013, 2014; see also Supplementary 
Materials). Probe and primer sequences were purchased from 
Eurofins MWG-Operon and are summarized in Table 1. Relative 
target gene expression was calculated according to the 2(-Delta 
Delta C[T]) method (Livak and Schmittgen, 2001), and the data was 
expressed and analyzed as percentage of mRNA levels in control 
offspring. Gene expression was examined in the medial prefron-
tal cortex (mPFC; including the anterior cingulate, prelimbic, and 
infralimbic subregions; bregma: +2.3 to +1.3 mm), striatum (Str; 
including dorsomedial and lateral caudate putamen; bregma +1.5 
to +0.5 mm), dorsal hippocampus (dHPC; bregma −1.5 to −2.5 mm), 
and ventral hippocampus (vHPC; bregma −2.5 to −3.5 mm).
Working Memory in a Spatial Novelty Preference 
Y-Maze Paradigm
Working memory was tested using a spatial novelty preference 
task in the Y-maze as established before (Bitanihirwe, Weber, 
et al., 2010). The spatial novelty preference test in the Y-maze 
assesses spatial working memory and uses the natural tendency 
of rodents to explore novel over familiar spatial environments 
(Dellu et  al., 1992). The apparatus and test protocol are fully 
described in the Supplementary Materials.
Social Interaction Test
The test of social interaction was performed in a modified 
Y-maze as fully described in the Supplementary Materials. The 
test consisted of two phases, namely the dummy phase and the 
novelty phase, which measured social approach behavior and 
social recognition, respectively. During the first phase (dummy 
phase), the test mouse could freely explore an unfamiliar 
C57BL6/N mouse (live mouse) and an inanimate object (dummy 
mouse). The percent of time spent with the live mouse was cal-
culated by the formula (time spent with the live mouse/(time 
spent with the live mouse + time spent with the dummy object)) 
× 100 and was used to assess relative exploration time between 
a congenic mouse and an inanimate dummy object. During 
the second phase (novelty phase), the test mouse could freely 
explore another unfamiliar C57BL6/N mouse (novel mouse) and 
Table 1. Primer Sequences Used in the Real-Time Polymerase Chain Reaction Analyses.
Gene Forward Primer Reverse Primer  Probe
α1 5’-TGAGAGCTGAATGCCCAATG-3’ 5’-TCTGCTACAACCACTGAACG-3’ 5’-CCTGCCCACTAAAATTCGGAAGCTATGC-3’
α2 5’-CCATGAGGCTTACAGTCCAAG-3’ 5’-ACGGAGTCAGAAGCATTGTAAG-3’ 5’-CGTAGCTTCCAAATTTCAGTGGGCA-3’
α3 5’-ACAATATGACCACACCCAACA-3’ 5’-AGCTTCCAAACTTCAGTGGG-3’ 5’-CAATACACGCTGAATGCCCCATGC-3’
α4 5’-GCCTGCCCTTTGAAATTTGG-3’ 5’-GATACAGTCTGCCCAATGAGG-3’ 5’-ATCTACACCTGGACCAAAGGCCC-3’
α5 5’-GGGAATGGACAATGGAATGC-3’ 5’-TGTCATTGGTCTCGTCTTGTAC-3’ 5’-CATTTGCGAAAAGCCAAAGTGACTGGA-3’
36B4 5’-AGATGCAGCAGATCCGCAT-3’ 5’-GTTCTTGCCCATCAGCACC-3’ 5’-CGCTCCGAGGGAAGGCCG-3’
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the familiar live mouse previously used in the dummy phase. 
This phase served as a measure of social recognition. The per-
cent of time spent with the novel mouse was calculated by the 
formula (time spent with the novel mouse/(time spent with the 
novel mouse + time spent with the familiar mouse)) × 100 and 
used to assess relative exploration time between the familiar 
and unfamiliar congenic mouse.
Amphetamine Sensitivity Test
An AMPH-induced locomotor hyperactivity test in the open field 
was used to assess the animals’ behavioral response to acute 
dopaminergic stimulation. The test apparatus and protocol are 
fully described in the Supplementary Materials. D-amphetamine 
sulfate (Sigma–Aldrich) was dissolved in isotonic 0.9% NaCl solu-
tion to achieve the desired concentration for injection. The AMPH 
concentration was administered via the i.p. route at a dose of 
2.5 mg/kg. The dose was selected based on our previous stud-
ies showing that poly(I:C) offspring display enhanced locomotor 
responses to AMPH at this dose (e.g., Meyer et al., 2005, 2008).
SH-053-2’F-S-CH3 Preparation and Administration
A detailed description of SH-053-2’F-S-CH3 synthesis has 
been described previously (Cook et  al., 2009). Synthesis of 
(S)-ethyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]
imidazo[1,5-a][1,4]diazepine-3-carboxylate was performed at 
the Department of Chemistry and Biochemistry, University of 
Wisconsin, Milwaukee, WI. SH-053-2′F-S-CH3 has been demon-
strated to have a greater relative affinity for α5 (Ki  =  19.2), α2 
(Ki = 33.3), and α3 (Ki = 291.5) compared with the relative affinity 
for α1 (Ki = 468.2; Fischer et al., 2010; Savić et al., 2010). Moreover, 
SH-053-2’F-S-CH3 has been shown to have a greater efficacy at 
α5 (218/389), α2 (170/348), and α3 (138/301) compared with the 
relative efficacy at α1 (116/164; efficacy expressed as percent-
age of control current at 100nM and 1μM; Fischer et al., 2010; 
Savić et al., 2010). SH-053-2’F-S-CH3 was dissolved with the aid 
of sonication in a solvent containing 85% deionized water, 14% 
propylene glycol, and 1% Tween 80. Corresponding VEH solution 
consisted of the solvent only. SH-053-2’F-S-CH3 was adminis-
tered at a dose of 15 or 30 mg/kg (i.p.) according to dose ranges 
reported previously (e.g., Savić et  al., 2010). All solutions were 
freshly prepared on the day of administration and were injected 
using an injection volume of 5ml/kg (i.p.).
Statistical Analysis
All gene expression (real-time PCR) data were analyzed using 
independent student’s t tests (two-tailed). In the Y-maze work-
ing memory test, the relative time spent in the novel arm and 
distance moved during the choice phase were analyzed using 
a 2 × 3 (prenatal treatment × drug treatment) analysis of vari-
ance (ANOVA). The data obtained in the social interaction test 
were separately analyzed for the two successive phases. In the 
first phase, a 2 × 3 (prenatal treatment × drug treatment) ANOVA 
of the percent of time spent with the live mouse was used to 
assess relative exploration time between a congenic mouse and 
an inanimate dummy object. In the second phase, a 2 × 3 (pre-
natal treatment × drug treatment) ANOVA of the percent time 
spent with the unfamiliar mouse was used to assess the relative 
exploration time between a novel congenic mouse and a famil-
iar congenic mouse. In the AMPH sensitivity test, the distance 
moved was expressed as a function of 5 min bins and analyzed 
using a 2 × 3  × 6 (prenatal treatment × drug treatment × bins) 
repeated-measure ANOVA for the initial pre-AMPH phase, and 
using a 2 × 3 × 12 (prenatal treatment × drug treatment × bins) 
repeated-measure ANOVA for the subsequent AMPH phase. All 
ANOVAs were followed by Scheffe’s post hoc comparisons when-
ever appropriate. Statistical significance was set at p < 0.05. All 
statistical analyses were performed using the statistical software 
StatView (SAS Institute Inc., version 5.0) implemented on a PC 
running the Windows XP operating system.
Results
Effects of Prenatal Immune Activation on the Gene 
Expression Profile of the GABAA Receptor α1–5 
Subunits
We first determined the gene expression levels of the α1–5 subu-
nits of the GABAA receptor in the mPFC, Str, dHPC, and vHPC of 
prenatally poly(I:C)–exposed and control offspring. As summa-
rized in Figure 1, poly(I:C) offspring displayed a significant reduc-
tion in the expression levels of the α2 (-15%; p < 0.01, t18 = 3.76), 
α4 (-20%; p < 0.01, t18 = 2.91), and α5 (-15%; p < 0.05, t18 = 2.73) 
subunits in the mPFC compared to controls. Moreover, prenatal 
poly(I:C) treatment significantly increased the expression of α3 
in the mPFC by 23% (p < 0.05, t18 = 2.70; Figure 1). Prenatal poly(I:C) 
exposure did not significantly affect the expression levels of the 
α1–5 subunits in the Str or dHPC (Figure  1). Poly(I:C) offspring 
displayed, however, a significant increase in the expression lev-
els of the α1 (+20%; p < 0.01, t18 = 2.93) and α2 (+25%; p < 0.01, 
t18 = 2.96) subunits in the vHPC relative to controls (Figure 1).
Effects of SH-053-2’F-S-CH3 on Working Memory 
Deficits Induced by Prenatal Immune Activation
We evaluated possible pro-cognitive effects of SH-053-2’F-
S-CH3 using a spatial-recognition working-memory test in the 
Y-maze. The critical measure of spatial-recognition memory is 
the relative time spent in the novel (previously unexplored) arm 
during the choice phase of this test. As expected, VEH-treated 
control offspring displayed a noticeable preference towards the 
novel arm, indicating intact working memory in these animals 
(Figure 2A). Poly(I:C) offspring exhibited a significant reduction 
in this measure regardless of whether they were treated with 
VEH or SH-053-2’F-S-CH3 (Figure  2A), suggesting that the PAM 
failed to restore working memory deficits in poly(I:C) offspring. 
Moreover, administration of the higher dose of SH-053-2’F-S-CH3 
(30 mg/kg) in prenatal control offspring also impaired working 
memory (Figure 2A), with both groups regressing to chance levels 
of performance after treatment with the PAM. ANOVA of relative 
time spent in the novel arm revealed a significant main effect 
of prenatal treatment [F(1,62) = 7.51, p  < 0.01], drug treatment 
[F(2,62) = 14.45, p < 0.001], and their interaction [F(2,62) = 4.16, 
p  <  0.05]. Subsequent post hoc analysis confirmed the signifi-
cant difference between VEH-treated control and poly(I:C) off-
spring (p  <  0.01); between VEH-treated control offspring and 
poly(I:C) offspring treated with SH-053-2’F-S-CH3 (p-values < 
0.001); and between VEH-treated control offspring and control 
offspring treated with SH-053-2’F-S-CH3 at 30 mg/kg (p < 0.001; 
see Figure 2A).
Prenatal poly(I:C) exposure did not significantly affect the dis-
tance moved during the Y-maze test (Figure 2B). Administration 
of SH-053-2’F-S-CH3, however, led to an increase in the total dis-
tance moved independent of the prenatal treatment histories 
(Figure 2B), as supported by the significant main effect of drug 
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Figure 1. Prenatal immune activation alters the gene expression profile of the γ-aminobutyric acid (GABAA) receptor α1–5 subunits in the medial prefrontal cortex and 
ventral hippocampus. The graphs depict the individual 2(-Delta C[T]) values for the medial prefrontal cortex (mPFC), striatum (Str), dorsal hippocampus (dHPC), and 
ventral hippocampus (vHPC) of control (CON) and polyriboinosinic-polyribocytidilic acid–exposed (POL) offspring. CON: n = 11; POL: n = 9; for each region and subunit. 
*p < 0.05 and **p < 0.01. All values are means ± standard error of the mean.
Figure 2. SH-053-2′F-S-CH3 administration produces working memory deficits in the Y-maze spatial recognition paradigm in both control and polyriboinosinic-polyri-
bocytidilic acid [POL] offspring. (A) The bar plot depicts the percent of time spent in the novel (previously unexplored) arm during the choice phases of the test following 
vehicle (0 mg/kg SH-053-2′F-S-CH3) or SH-053-2′F-S-CH3 (at 15 or 30 mg/kg) treatment in control (CON) and POL offspring. The dashed line represents the chance level. 
*p < 0.05, **p < 0.01 and ***p < 0.001, based on Scheffe’s post hoc tests. (B) The graph shows the total distance moved during the choice phases of the test. #p < 0.01 and 
§p < 0.001, reflecting the increase in distance moved displayed by animals treated with 15 mg/kg and 30 mg/kg SH-053-2′F-S-CH3, respectively, relative to vehicle treat-
ment; p-values are based on Scheffe’s post hoc tests. CON, 0 mg/kg, n = 12; CON, 15 mg/kg, n = 11; CON, 30 mg/kg, n = 11; POL, 0 mg/kg, n = 12; POL, 15 mg/kg, n = 11; and 
POL, 30 mg/kg, n = 11. All values are means ± standard error of the mean.
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treatment in the ANOVA of total distance moved [F(2,62) = 5.67, 
p < 0.01]. Subsequent post hoc tests verified the significant differ-
ence between animals treated with VEH and SH-053-2’F-S-CH3 
at 15 mg/kg (p < 0.05), as well as between animals treated with 
VEH and SH-053-2’F-S-CH3 at 30 mg/kg (p < 0.01; see Figure 2B).
Effects of SH-053-2’F-S-CH3 on Social Interaction and 
Recognition Deficits Induced by Prenatal Immune 
Activation
In a next step, we investigated whether SH-053-2’F-S-CH3 would 
be effective in normalizing social interaction deficits that are 
typically seen following a prenatal immune challenge. The rela-
tive exploration time between an unfamiliar congenic mouse 
and an inanimate dummy object was used to assess social 
approach behavior in the first phase of the social interaction 
test. As shown in Figure 3A, prenatal control offspring displayed 
a clear preference towards the unfamiliar live mouse regardless 
of whether they were treated with VEH or SH-053-2’F-S-CH3. 
Such social approach behavior was significantly disrupted in 
poly(I:C) offspring, independent of whether they received VEH or 
SH-053-2’F-S-CH3 treatment. Indeed, poly(I:C) offspring did not 
display a clear preference towards the unfamiliar live mouse, 
such that the percent of time spent with the live mouse was 
approximately at the 50% (chance) level in these animals (see 
Figure 3A). ANOVA of the percent time spent with the live mouse 
revealed only a significant main effect of prenatal treatment 
[F(1,62) = 7.05, p < 0.01].
In the second phase of the test, the relative exploration time 
between the previously explored live mouse and a novel unfamil-
iar mouse was then used to assess social recognition memory. 
Both control and poly(I:C) offspring treated with VEH displayed a 
clear preference towards the novel unfamiliar mouse relative to 
the previously explored mouse, suggesting that prenatal poly(I:C) 
exposure did not affect social recognition memory (see Figure 3B). 
Administration of SH-053-2’F-S-CH3, however, significantly 
Figure 3. SH-053-2′F-S-CH3 does not impair social approach behavior but interferes with social recognition performance in both control and polyriboinosinic-polyr-
ibocytidilic acid [poly(I:C); POL] offspring. (A) Behavioral outcomes in the social approach test (dummy phase). The line plot shows absolute exploration time of an 
unfamiliar live mouse (M) and inanimate dummy object (D) separately for control (CON) and (POL) offspring treated with vehicle (0 mg/kg SH-053-2′F-S-CH3) or SH-053-
2′F-S-CH3 (at 15 or 30 mg/kg). The bar plot depicts the percent time spent with the live mouse in the social approach test. *p < 0.01, reflecting the significant main effect 
of prenatal poly(I:C) exposure. (B) Behavioral outcomes in the social recognition test (novelty phase). The line plot shows absolute exploration time of a novel live mouse 
(N) and the familiar live mouse (F) separately for CON and POL offspring treated with vehicle or SH-053-2′F-S-CH3 (at 15 or 30 mg/kg). The bar plot depicts the percent 
time spent with the novel mouse in the social recognition test. §p < 0.01, reflecting the significant decrease displayed by animals treated with 30 mg/kg SH-053-2′F-S-CH3 
relative to vehicle-treated animals. CON, 0 mg/kg, n = 11; CON, 15 mg/kg, n = 12; CON, 30 mg/kg, n = 11; POL, 0 mg/kg, n = 11; POL, 15 mg/kg, n = 11; and POL, 30 mg/kg, 
n = 12. All values are means ± standard error of the mean, and all p-values are based on Scheffe’s post hoc tests.
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impaired social recognition memory regardless of the prenatal 
treatment histories (Figure 3B). Indeed, the percent of time spent 
with the novel unfamiliar mouse decreased with increasing doses 
of SH-053-2’F-S-CH3, leading to a significant main effect of drug 
treatment in the ANOVA of this measure [F(2,62) = 5.42, p < 0.01]. 
Subsequent post hoc analyses confirmed the significant differ-
ence between animals treated with VEH and SH-053-2’F-S-CH3 at 
15 mg/kg (p < 0.05), as well as between animals treated with VEH 
and SH-053-2’F-S-CH3 at 30 mg/kg (p < 0.01; Figure 3B).
Effects of SH-053-2’F-S-CH3 on AMPH 
Hypersensitivity Induced by Prenatal Immune 
Activation
Finally, we also explored whether SH-053-2’F-S-CH3 may be 
effective in normalizing potentiated AMPH sensitivity typi-
cally emerging following prenatal immune activation. For this 
purpose, we assessed the effects of the PAM on AMPH-induced 
hyperactivity in the open field test.
Neither prenatal poly(I:C) exposure nor SH-053-2’F-S-CH3 
pretreatment significantly affected the total distance moved 
during the initial 30 min period of the open field test (Figure 4). 
Poly(I:C) and control offspring treated with the higher dose of 
SH-053-2’F-S-CH3 (30 mg/kg) tended to show higher locomotor 
activity scores during this initial testing period, but this effect 
did not attain statistical significance (Figure  4). ANOVA of the 
total distance moved only revealed a significant main effect of 
bins [F(5,310) = 9.04, p < 0.001], reflecting the overall changes in 
locomotor activity resulting from habituation to the open field.
Subsequent administration of AMPH led to a general increase 
in the total distance moved, as supported by the main effect of 
bins [F(11,682) = 77.78, p < 0.001], in the AMPH phase of the test. 
VEH-treated poly(I:C) offspring showed a marked potentiation 
of the AMPH-induced hyperactivity response compared with 
the locomotor-enhancing effects of AMPH in VEH-treated con-
trol offspring (Figure  4). Most interestingly, SH-053-2’F-S-CH3 
pretreatment fully normalized the potentiation of the AMPH-
induced hyperactivity response in poly(I:C) offspring, without 
significantly affecting the locomotor-enhancing effects of AMPH 
exposure in control offspring (Figure  4). These impressions 
were supported by ANOVA revealing a significant interaction 
between prenatal treatment and drug treatment [F(2,62) = 3.56, 
p < 0.05], and a significant three-way interaction between pre-
natal treatment, drug treatment, and bins [F(22,682)  =  1.60, 
p < 0.05]. Subsequent post hoc analyses of the mean distance 
moved across the 60 min AMPH test period confirmed a sig-
nificant difference between VEH-treated control and poly(I:C) 
offspring (p  <  0.05), as well as between VEH-treated poly(I:C) 
offspring and poly(I:C) offspring treated with SH-053-2’F-S-CH3 
(p-values < 0.05).
Discussion
The present study confirms that prenatal immune activation 
by the viral mimic poly(I:C) alters GABAergic gene expression 
in the adult central nervous system (Richetto et al., 2013, 2014). 
Here, we replicated our initial findings of impaired α2, α4, and 
α5 gene expression in the mPFC of adult poly(I:C) offspring 
Figure 4. SH-053-2′F-S-CH3 selectively reverses the potentiated amphetamine (AMPH) locomotor response in polyriboinosinic-polyribocytidilic acid (POL) offspring. 
The line plots show the distance moved in the open field as a function of 5 min bins during the initial habituation phase and the subsequent AMPH (2.5 mg/kg, i.p.) 
exposure phase separately for control (CON) and (POL) offspring treated with vehicle (0 mg/kg SH-053-2′F-S-CH3) or SH-053-2′F-S-CH3 (at 15 or 30 mg/kg). The bar plot 
depicts the mean distance moved during the AMPH exposure phase for all groups. *p < 0.05 and **p < 0.01, based on Scheffe’s post hoc analyses. CON, 0 mg/kg, n = 11; 
CON, 15 mg/kg, n = 11; CON, 30 mg/kg, n = 12; POL, 0 mg/kg, n = 11; POL, 15 mg/kg, n = 12; and POL, 30 mg/kg, n = 11. All values are means ± standard error of the mean.
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(Richetto et al., 2014). Similar reductions in cortical α4 and α5 
gene expression have been found in schizophrenia and other 
neurodevelopmental disorders with prenatal infectious eti-
ologies, including autism (Duncan et  al., 2010; Beneyto et  al., 
2011; Blatt and Fatemi, 2011). On the other hand, our findings 
do not parallel the reports of decreased and increased α1 and 
α2 mRNA levels, respectively, in the cortical areas of schizo-
phrenia patients (Hashimoto, Arion, et al., 2008; Beneyto et al., 
2011). Adult poly(I:C) offspring, however, displayed a significant 
increase in α1 and α2 gene expression in the vHPC, the latter 
being consistent with previous immunohistochemical stud-
ies showing increased α2 protein expression in the vHPC of 
poly(I:C)-exposed offspring (Meyer et  al., 2008). Interestingly, 
the dHPC was largely spared by the prenatal manipulation 
with respect to GABAA receptor alterations, and similar region-
specific effects have been reported for other GABAergic mark-
ers such as parvalbumin and reelin (Meyer et al., 2008). It thus 
appears that the vHPC may be more susceptible to the disrupt-
ing effects of prenatal immune challenge compared to the dHPC. 
This notion fits well with accumulating evidence supporting a 
pivotal role of ventral hippocampal GABAergic abnormalities 
in developmental psychiatric disorders such as schizophrenia 
(Steullet et al., 2010; Grace, 2010, 2012; Lodge and Grace, 2011).
Based on the GABAergic effects reported here and previ-
ously (Meyer et  al., 2008; Richetto et  al., 2014), we speculated 
that administration of SH-053-2’F-S-CH3, a positive allosteric 
modulator with high affinity for the α2 and α5 (and to a lesser 
extent for α3) subunits of the GABAA receptor, may exert ben-
eficial effects against prenatal infection-induced behavioral 
abnormalities. Consistent with previous studies (Bitanihirwe, 
Peleg-Raibstein, et  al., 2010; Bitanihirwe, Weber, et  al., 2010; 
Connor et  al., 2012; Richetto et  al., 2013, 2014), poly(I:C) off-
spring were found to display impaired working memory in the 
Y-maze spatial recognition test and reduced social approach 
behavior in the social interaction test. Furthermore, they exhib-
ited increased sensitivity to the locomotor-enhancing effects 
of the indirect dopamine-receptor agonist AMPH compared to 
control offspring, as reported before (Zuckerman et  al., 2003; 
Meyer et  al., 2005, 2008; Piontkewitz et  al., 2011). In contrast 
to our hypothesis, the PAM SH-053-2’F-S-CH3 did not mitigate 
the poly(I:C)-induced working memory and social interaction 
deficits, two behavioral abnormalities commonly found in 
people with schizophrenia and related disorders (Lewis and 
Moghaddam, 2006; Foussias and Remington, 2010). In fact, 
SH-053-2’F-S-CH3 administration to prenatal control offspring 
impaired performance in the Y-maze working memory and 
social interaction tests. In the latter, SH-053-2’F-S-CH3 pretreat-
ment led to a selective impairment in social recognition but 
not social approach behavior, suggesting that the drug nega-
tively affected short-term retention of social cues rather than 
social approach behavior per se. Several previous studies have 
shown that prenatal poly(I:C)-induced cognitive deficits in rats 
and mice can be restored or even prevented by atypical antip-
sychotic drugs such as clozapine and risperidone (Zuckerman 
et al., 2003; Ozawa et al., 2006; Piontkewitz et al., 2009; Meyer 
et  al., 2010). Therefore, one implication is that a normaliza-
tion of prenatal poly(I:C)-induced spatial and social recogni-
tion deficits would require a modulation of neurotransmitter 
systems that go beyond those primarily mediated by GABAA 
receptors. However, one clear limitation of our study is that the 
assessment of cognitive functions was performed using a test 
that is primarily based on spontaneously-motivated behavior. 
Additional investigations are thus warranted to extend our 
findings to other cognitive domains.
The detrimental effects of SH-053-2’F-S-CH3 on cognitive 
functions revealed here are in contrast to previous findings in 
rats suggesting that this PAM does not negatively affect spatial 
reference memory as assessed in the Morris water maze test 
(Savić et  al., 2010). We have no parsimonious explanation for 
this discrepancy, but it could be related to differential cognitive 
processes involved (short-term working memory versus long-
term reference memory) and/or potentially important species 
differences (mice versus rats). The amnesic effects of SH-053-
2’F-S-CH3 on short-term spatial- and social-recognition memory 
may also seem surprising in view of previous findings indicat-
ing that GABAergic agonists acting at the α2/α3 subunits induce 
pro-cognitive effects (Lewis et al., 2008; Castner et al., 2010). It 
needs to be pointed out, however, that the pro-cognitive effects 
of α2/α3 agonists remain controversial (Buchanan et al., 2011). 
Furthermore, accumulating evidence suggests that reduced and 
increased activity of the α5 subunit of the GABAA receptor facili-
tates and impairs cognitive functions, respectively (Collinson 
et al., 2002; Crestani et al., 2002; Dawson et al., 2006; Tan et al., 
2011; Redrobe et  al., 2012; Milić et  al., 2013). Hence, the nega-
tive consequences of SH-053-2′F-S-CH3 on short-term memory 
revealed here may also be explained by positive modulation of 
the α5 subunit, given that the drug is characterized by strong 
α5 activity (Fischer et al., 2010; Savić et al., 2010). One clear pos-
sibility to further test this hypothesis would be to evaluate 
whether compounds with selective affinity for the α5 subunit 
would share such cognitive disruptive effects. Intriguingly, the 
R-isomer of the PAM used here (namely the SH-053-2′F-R-CH3 
isomer) shows such selectivity for the α5 subunit (Cook et al., 
2009; Fischer et al., 2010; Savić et al., 2010; Gill et al., 2011), and 
therefore, it would provide a reasonable pharmacological tool to 
address these issues. In such attempts, it would be important to 
compare various dose ranges because the S-isomer (SH-053-2′F-
S-CH3) and R-isomer (SH-053-2′F-R-CH3) differ in their affinity 
for α5 (Cook et al., 2009; Fischer et al., 2010; Savić et al., 2010; Gill 
et al., 2011). Hence, administration of the S-isomer (SH-053-2′F-
S-CH3) and R-isomer (SH-053-2′F-R-CH3) at the same dose may 
differentially influence cognitive functions due to distinct α5 
affinities.
Despite the inability of SH-053-2′F-S-CH3 to correct prenatal 
infection-induced cognitive impairments, it was highly effective 
in mitigating AMPH hypersensitivity in adult poly(I:C) offspring 
without concomitant effects in prenatal control offspring. AMPH 
exposure can produce psychosis-like states in healthy human 
subjects and exacerbate existing psychoses in patients with 
schizophrenia (Laruelle, 2000). Moreover, potentiation of AMPH-
induced dopamine release in schizophrenia patients tends to 
correlate with the severity of positive symptoms (Laruelle and 
Abi-Dargham, 1999). The efficacy of SH-053-2’F-S-CH3 to correct 
the poly(I:C)-induced potentiation of AMPH sensitivity may thus 
be especially relevant for attempts to establish and validate 
GABA-based treatments targeting positive symptoms.
Our data are also highly congruent with previous find-
ings showing that acute treatment with a selective α5 GABAA-
receptor PAM (namely the SH-053-2′F-R-CH3 isomer) can fully 
reverse AMPH hypersensitivity and hyperactivity of ventral 
midbrain dopamine neurons in the MAM-based neurodevelop-
mental model of schizophrenia (Gill et al., 2011). The fact that 
prenatal MAM-induced AMPH hypersensitivity can be normal-
ized by a selective α5 GABAA-receptor PAM indicates that the 
beneficial effects of SH-053-2’F-S-CH3 revealed here may also 
be largely attributable to the drug’s activity at the α5 subunit. 
The congruent findings obtained in the prenatal poly(I:C) and 
MAM administration models emphasize the possibility that 
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alterations in the adult central GABA system may represent a 
critical pathological convergence point for various prenatal 
adversities implicated in the etiology of neurodevelopmental 
brain abnormalities (Volk and Lewis, 2013). These models also 
support the hypothesis that there is a causal link between 
altered signaling at α subunits of the GABAA receptor and the 
emergence of schizophrenia-relevant dysfunctions in neurode-
velopmentally compromised offspring (Stan and Lewis, 2012; 
Volk and Lewis, 2013), at least with respect to AMPH hypersen-
sitivity and related hyperdopaminergic functions. Consistent 
with this notion, reduced GABAergic signaling at the α5 subunit 
has previously been implicated in other dopamine-dependent 
behaviors: genetically-induced deficits in α5 expression impair 
pre-pulse inhibition of the acoustic startle reflex (Hauser et al., 
2005) and selective associative learning as assessed by the latent 
inhibition paradigm (Gerdjikov et al., 2008).
According to a recent hypothesis (Lodge and Grace, 2011; 
Grace, 2012), disinhibition of the ventral hippocampus result-
ing from intrahippocampal impairments in GABAergic signaling 
could lead to a pathological hyperactivity of the (ventral) hip-
pocampus and subsequent increase in mesoaccumbal dopa-
mine system function. It needs to be evaluated further whether 
or not similar mechanisms may underlie the prenatal poly(I:C)-
induced AMPH hypersensitivity. Likewise, the mechanisms by 
which SH-053-2′F-S-CH3 can ameliorate altered AMPH sensitiv-
ity in immune-exposed offspring still await exploration. Related 
to this, it is possible that behavioral functions critically regulated 
by ventral hippocampal activity could benefit from preferential 
α5 GABAA-receptor PAMs, whereas such pharmacological com-
pounds may lack therapeutic efficacy for cognitive functions 
that are more directly linked to neuronal activity in the prefron-
tal cortex, a site with lower α5 GABAA receptor expression. It is 
also conceivable that region-specific increases in the expression 
of distinct GABAA receptor α subunits (e.g., increased prefrontal 
α3 or ventral hippocampal α2 expression) may occlude potential 
effects of SH-053-2’F-S-CH3, at least in offspring with immune-
mediated neurodevelopmental abnormalities.
In conclusion, our study provides preclinical support for the 
use of benzodiazepine-positive allosteric modulators in the 
symptomatic treatment of AMPH hypersensitivity that emerges 
following (immune-mediated) neurodevelopmental disruption. 
Together with the recent findings obtained in the prenatal MAM 
administration model (Gill et  al., 2011), our data suggest that 
positive allosteric modulation of the GABAA receptor α5 subunit 
may be particularly useful in mitigating pathological overac-
tivity of the dopaminergic system. At the same time, however, 
our study falls short in detecting possible pro-cognitive effects 
of PAM treatment with selective activity at the α2, α3, and α5 
subunits of the GABAA receptor. The lack of such pro-cognitive 
effects may raise concerns regarding the effective use of some 
types of GABA subunit selective compounds that target multiple 
pathological domains that involve the co-existence of psychotic, 
social, and cognitive dysfunctions.
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